Active Comparator-Controlled Study to Assess Safety and Efficacy of ISIS-FXIRx in Total Knee Arthroplasty

NCT01713361 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

315

Enrollment

INDUSTRY

Sponsor class

Conditions

Venous Thromboembolism

Interventions

DRUG: ISIS-FXIRx Dose #2
DRUG: ISIS-FXIRx Dose #3
DRUG: Enoxaparin

Sponsor

Ionis Pharmaceuticals, Inc.